Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes. Indiplon was licensed from DOV Pharmaceuticals in 1998. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.
Dainnipon Sumitomo Pharma Co's Corporate Mission is to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. Dainippon Sumitomo Pharma Co's news releases are available through the website via the Internet at http://www.ds-pharma.co.jp/english.
In addition to historical facts, this press release may contain
forward- looking statements that involve a number of risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those indicated in the forward looking statements are risks
and uncertainties associated with Neurocrine's business and finances and
research programs in general including, but not limited to, risk and
uncertainties associated with the Company's indiplon program and planned
commercialization activities, risk that regulatory authorities may find our
resubmission of the indiplon capsule NDA incomplete or insufficient or
otherwise unapprovable or that approval may be delayed; risk that following
approval of indiplon capsules, commercialization may be delayed for any of
a number of reasons including market condit
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved